The molecular mechanism of action of the CR6261-Azichromycin combination found through computational analysis.

ABSTRACT:

Background

CR6261 was found in 2008 and F10 was found in 2009. In 2010 Friesen et al experimentally showed that Oseltamivir/Zanamivir may improve the therapeutic efficacy of CR6261. As a result, the use of CR6261 combined with a drug to provide an antibody-based therapy against all influenza A viruses was proposed. Although CR8020 may neutralize group 2 influenza viruses and FI6 may neutralize both group 1 and group 2 influenza viruses as determined in 2011, the insight of Friesen et al is still interesting. Here, we address the following questions: how to uncover the molecular mechanism of a drug, which improves the therapeutic efficacy of mAbs and how to find drugs that enable CR6261 (CR8020, F10) to become a universal mAb.

Methods and findings

Using the 3D structures of 3

SUBMITTER: Cui W 

PROVIDER: S-EPMC3365099 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature